Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Gabriel Etienne, Naoto Takahashi, Inho Kim, David Andorsky, Ghayas C. Issa, Felice Bombaci, Shruti Kapoor, Rajendra Jinwal, Lillian Yau, Richard Larson

Blood (2024) 144 (Supplement 1): 475.

https://doi.org/10.1182/blood-2024-203757

Published: 2024

Journal Articles

Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors

Torsten Dahlén, Camille C.B. Kockerols, Germano Ferreira, Peter E. Westerweel, Jiri Mayer, Alex Allepuz, David Wormser, Lillian Yau, Daniela Žácková

Blood (2022) 140 (Supplement 1): 3889–3890.

https://doi.org/10.1182/blood-2022-163151

Published: 2022

Journal Articles

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence

Torsten Dahlen, Camille Kockerols, Germano Ferreira, Peter E. Westerweel, Jiří Mayer, Tarek Sahmoud, David Wormser, Lillian Yau, Daniela Žácková

Blood (2021) 138 (Supplement 1): 1485.

https://doi.org/10.1182/blood-2021-148773

Published: 2021

Journal Articles

A Systematic Literature Review of Overall Survival and Delivered Dose Intensity in Cancer Patients Receiving Chemotherapy and G-CSF in Randomized Control Trials

Gary H. Lyman, MD MPH, FRCP, Lillian Yau, Roumen Nakov, Andriy Krendyukov

Blood (2017) 130 (Supplement 1): 3424.

https://doi.org/10.1182/blood.V130.Suppl_1.3424.3424

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence

A Systematic Literature Review of Overall Survival and Delivered Dose Intensity in Cancer Patients Receiving Chemotherapy and G-CSF in Randomized Control Trials

Email alerts

ASH Publications

American Society of Hematology

Update search

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence

A Systematic Literature Review of Overall Survival and Delivered Dose Intensity in Cancer Patients Receiving Chemotherapy and G-CSF in Randomized Control Trials

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only